ESSA Pharma Inc EPIX

Healthcare Biotechnology

ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.

NDAQ:EPIX - Post by User

ESSA Pharma Inc

<< Previous

Bullboard Posts

Next >>

Post by SilentRiveron Aug 24, 2020 6:03am

130 Views

Post# 31444526

Insider buying

Filed 2020-08-21 15:43 Tx date 2020-08-17	$EPI ESSA Pharma Inc.	BERGER, FRANKLIN MILAN 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$680,000 +100,000 vol $6.80 each	764,420
Filed 2020-08-21 15:42 Tx date 2020-08-17	$EPI ESSA Pharma Inc.	BERGER, FRANKLIN MILAN 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$47,600 +7,000 vol $6.80 each	664,420